Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZYDUSLIFE.NS
BuyPremium GrowerZydus Lifesciences Limited · Healthcare · India · $12.1B · Avg Vol: $19M/d
68
StockRankGet insider-trade alerts
Q
62
V
34
M
66
P/E (TTM)
25.1x
ROE
18.6%
D/E
0.4x
Dividend %
0.1%
COMPANY DESCRIPTION
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 168.8B | 190.2B | 225.7B | 267.2B | 16.5% | 286.9B | 312.4B | 344.6B | 13.6% |
| EPS (INR) | 19.30 | 38.14 | 44.97 | 50.09 | 37.4% | 45.05 | 37.69 | 45.63 | -4.6% |
| Shares | 1.0B | 1.0B | 1.0B | 1.0B | -0.6% | 997.5M | — | — | — |
| Debt | 11.9B | 8.0B | 32.1B | 125.0B | 118.7% | 125.6B | — | — | — |
| Equity | 175.2B | 198.3B | 239.5B | 271.1B | 15.7% | — | — | — | — |
| Op CF | 26.9B | 32.0B | 67.8B | 21.2B | -7.7% | 21.2B | — | — | — |
| Inv CF | 15.3B | -14.8B | -83.6B | -83.0B | — | — | — | — | — |
| Fin CF | -44.0B | -17.8B | 20.0B | 58.1B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+1.1%
SMA 50SMA 200
Close
$11.81
RSI (14)
53.7
52W High
$12.63
From 52W High
0.9%
SCORE BREAKDOWN
Quality
62
ROIC
19.0%89.5
ROE
18.6%87.1
GP/Assets
39.3%77.1
Op. Margin
16.4%77.6
FCF/Assets
-1.1%42.6
Piotroski
431.0
Int. Cover
19.1x70.9
D/E Ratio
0.42x32.6
Current Ratio
1.27x18.9
Value
34
P/E (TTM)
25.1x49.0
EV/EBITDA
18.4x37.6
P/FCF
—N/A
P/B
4.2x34.6
P/S
3.9x48.9
Div Yield
0.1%1.6
Momentum
66
52W High %
94%91.0
RS 6M
27%83.8
SMA 50/200
1.14x81.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+10%27.0
Q Growth
-36%14.4
FUNDAMENTALS
Market Cap
$12.1B
P/E (Forward)
22.9x
Gross Margin
72.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZYDUSLIFE.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZYDUSLIFE.NS | Zydus Lifesciences Limited(you) | $12.1B | 68 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| DIVISLAB.NS | Divi's Laboratories Limited | $26.8B | 73 | Buy |
| DRREDDY.NS | Dr. Reddy's Laboratories Limited | $10.1B | 50 | Hold |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| TORNTPHARM.NS | Torrent Pharmaceuticals Limited | $19.9B | 52 | Hold |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%